Currently, inhibitors against the kinase P-TEFb (CDK9/CyclinT1) [30], histone methyltransferases DOT1L [31], and bromodomain and extra-terminal domain family of proteins [32] are undergoing clinical testing for AML, and inhibitors of the MENIN-MLL interaction have been described and are undergoing pre-clinical evaluation [33, 34]. The gene discussed is CDK9; the disease is acute myeloid leukemia.